



Version 2

Aug 17, 2020

# INSIGHT: a population scale COVID-19 testing strategy combining point-of-care diagnosis with centralised high-throughput sequencing V.2

Qianxin Wu<sup>1</sup>, Chenqu Suo<sup>1,2</sup>, Tom Brown<sup>3</sup>, Tengyao Wang<sup>4</sup>, Sarah Teichmann<sup>1,5</sup>, Andrew Bassett<sup>1</sup><sup>1</sup>Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK;<sup>2</sup>Department of Paediatrics, Cambridge University Hospitals, Hills Road, Cambridge CB2 0QQ, UK;<sup>3</sup>Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford OX1 3TA UK;<sup>4</sup>Department of Statistical Science, University College London, 1-19 Torrington Place, London WC1E 7HB, UK;<sup>5</sup>Department of Physics/Cavendish Laboratory, University of Cambridge, JJ Thomson Ave., Cambridge CB3 0HE, UK

1 Works for me

This protocol is published without a DOI.

Coronavirus Method Development Community

Chenqu Suo

## ABSTRACT

We present INSIGHT (Isothermal NASBA-Sequencing-based HIGH-throughput Test): a two-stage COVID-19 testing strategy, using a barcoded isothermal NASBA reaction that combines point-of-care diagnosis with next generation sequencing, aiming to achieve population-scale COVID-19 testing. INSIGHT combines the advantages of near-patient with centralised testing. Stage 1 allows a quick decentralised readout for early isolation of pre-symptomatic or asymptomatic patients. The same reaction products can then be used in a highly multiplexed sequencing-based assay in Stage 2, confirming the near-patient testing results and facilitating centralised data collection. Based on experiments using commercially acquired human saliva with spiked-in viral RNA as input, the INSIGHT platform gives Stage 1 results within one to two hours, using either fluorescence detection or a lateral flow (dipstick) readout, whilst simultaneously incorporating sample-specific barcodes into the amplification product. INSIGHT Stage 2 can be performed by directly pooling and sequencing all post-amplification barcoded Stage 1 products from hundreds of thousands of samples with minimal sample preparation steps. The 95% limit of detection (LoD-95) for INSIGHT is estimated to be below 50 copies of viral RNA per 20 µl of reaction. Our two-stage testing strategy is suitable for further development into a rapid home-based and point-of-care assay, and is potentially scalable to the population level.

## THIS PROTOCOL ACCOMPANIES THE FOLLOWING PUBLICATION

<https://doi.org/10.1101/2020.06.01.127019>

## PROTOCOL CITATION

Qianxin Wu, Chenqu Suo, Tom Brown, Tengyao Wang, Sarah Teichmann, Andrew Bassett 2020. INSIGHT: a population scale COVID-19 testing strategy combining point-of-care diagnosis with centralised high-throughput sequencing. **protocols.io**

<https://protocols.io/view/insight-a-population-scale-covid-19-testing-strate-bjrikm4e>

## MANUSCRIPT CITATION please remember to cite the following publication along with this protocol

<https://doi.org/10.1101/2020.06.01.127019>

## LICENSE

This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

## CREATED

Aug 14, 2020

LAST MODIFIED

Aug 17, 2020

PROTOCOL INTEGER ID

40458

#### MATERIALS

NAME	CATALOG #	VENDOR
QuickExtract DNA Extraction Solution	QE09050	Lucigen
NASBA liquid kit	SKU: NWK-1	Life Sciences Advanced Technologies Inc.
Tris (1 M) pH = 8 RNase free	AM9855G	Invitrogen - Thermo Fisher
Sodium Hydroxide	71687	Sigma-aldrich
1M MgCl <sub>2</sub>	AM9530G	Invitrogen - Thermo Fisher
2M KCl	AM9640G	Invitrogen - Thermo Fisher
DTT	43816	Sigma-aldrich
DMSO	276855	Sigma-aldrich
dNTP set 100 mM	10297018	Invitrogen - Thermo Fisher
NTP set 100 mM	R0481	Thermo Scientific
RNase H	M0297L	NEB
ProtoScript II reverse transcriptase	M0368S	NEB
T7 RNA polymerase	M0251L	NEB
BSA 20 mg/ml	B9000S	NEB
PCRD lateral flow assay	FG-FD51673	Abingdon Health
Qubit RNA HS Assay Kit	Q32852	Invitrogen - Thermo Fisher
PowerUp™ SYBR™ Green qPCR Master Mix	15340939	Applied Biosystems
Twist synthetic SARS-CoV-2 RNA control	Mt007544.1	Twist Bioscience
NASBA lyophilised kit	SKU: NLK	Life Sciences Advanced Technologies Inc.
Qubit dsDNA HS Assay Kit	Q32851	Invitrogen
Normal human saliva	MBS170210	MyBioSource
QIAquick PCR Purification Kit	28104	Qiagen
KAPA HiFi HotStart ReadyMix PCR Kit	KK2600	Kapa Biosystems
AMPure XP	A63882	Bechman Coulter
MiSeq Reagent Kits v2 (300-cycles)	MS-102-2002	illumina

#### MATERIALS TEXT

##### NASBA primers (P8) sequence:

FWD primer	CCAGCAACTGTTTG TGGACCTA
REV primer with T7 handle	aattctaatacgactcact atagggagaaggACAC CTGTGCCTGTTAAA CCAT
FWD primer with 5-nt barcode and Illumina handle	tgactggagttcagacgt gtgctcttccgatctnnnn nCCAGCAACTGTTT GTGGACCTA
REV primer with 5-nt barcode and T7 handle	aattctaatacgactcact atagggagaaggnnnnn ACACCTGTGCCTGT TAAACCAT

##### Toehold molecular beacon (2'-O-methyl RNA):

FAM-AUUGACAGUCUACUAAUUUGGUUAAAAACAAUGUGUCA-BHQ1dT-UUCAACUCAAUG-propyl

**P8 RNA capture oligos for PCRD:**

Probe A	FAM- AAAAGTCTACTAAT TTGGTTAAAA
Probe B	ACAAATGTGTCAAT TTCAACTTCA- Biotin

**Library construction PCR primers:**

P5 end primer	AATGATACGGCGA CCACCGAGATCTA CACNNNNNNNNAG CCAGCTCTGGAGA ATTCTAATACGACT CACTATAGGGAGA AGG
P7 end primer	CAAGCAGAAGACG GCATACGAGATNN NNNNNNGTGACTG GAGTTCAGACGTG TGCTCTTCCGATC T
Customised NGS primer (T7containing)	AGCCAGCTCTGGA GAATTCTAATACG ACTCACTATAGGG AGAAGG

## SAFETY WARNINGS

**\*\*\* IMPORTANT: This protocol has not been validated on patient samples and should not be used for clinical diagnosis without further validation and certification. \*\*\***

**1 Lysis of saliva samples**

Mix crude saliva (commercial pooled human saliva from healthy individuals) at 1:1 ratio with QuickExtract DNA Extraction Solution. Incubate at 95 °C for 5 min to ensure complete lysis of virus and inactivation of proteinase K.

**2 (Option A) NASBA Saliva lysate reaction with fluorescence detection**

Take 1 µl from the product of Step 1 (saliva lysate) and add into the NASBA reaction mixture (without the enzyme mix) to make a total volume of 15 µl. Reaction mixture can either be prepared in-house or from the Life Sciences NASBA liquid kit (see tables below) using one of the two temperature settings below.

- Reaction mixture without the enzyme mix is incubated at 65 °C for 2 min followed by a 10-min incubation at 41 °C. Following that, 5 µl enzyme mix is added into the reaction and incubated at 41 °C for a further of 90-120 min.
- Alternatively, reaction mixture without the enzyme mix is incubated at 95 °C for 5 min followed by a 10-min incubation at 41 °C. Following that, 5 µl enzyme mix is added into the reaction and incubated at 41 °C for a further 90-120 min.

A fluorescence plate reader (e.g. FluoSTAR) can be used to monitor the reaction in real-time, or as an endpoint assay.

	vol.	stock conc.	conc. in RM
Saliva lysate	1 µl		
primers*/beacon# mix	1 µl	500 nM each primer, 400 nM beacon	25 nM each primer, 20 nM beacon
spiked-in viral RNA/water	3 µl		
buffer (NECB-24)	6.7 µl		
nucleotide (NECN-24)	3.3 µl		
enzyme mix (NEC-1-24)	5 µl		
<b>total volume</b>	20 µl		

#### Life Sciences reaction mixture (RM)

\* Primer sequence available in Materials.

# Molecular beacon is reconstituted with annealing buffer (10 mM Tris pH 8 with 10 µM MgCl<sub>2</sub>) to the final concentration of 10 µM. Beacon is then annealed by incubation at 85 °C for 5 min, then gradual cooling to 4 °C by 0.1 °C/s before the NASBA reaction.

	vol.	stock conc.	conc. in RM
Saliva lysate	1 µl		
primers*/beacon# mix	1 µl	25 nM each primer 20 nM beacon	25 nM each primer 20 nM beacon
spiked-in viral RNA/water	4 µl		
buffer with DMSO*	5 µl		
nucleotide mix*	4 µl		
enzyme mix*	5 µl		
<b>total volume</b>	20 µl		

#### In-house reaction mixture (RM)

\* For detailed mixture composition, see tables below. Primer sequence available in Materials.

# Molecular beacon is reconstituted with annealing buffer (10 mM Tris pH 8 with 10 µM MgCl<sub>2</sub>) to the final concentration of 10 µM. Beacon is then annealed by incubation at 85 °C for 5 min, then gradual cooling to 4 °C by 0.1 °C/s before the NASBA reaction.

	vol.	stock conc.	conc. in RM
Tris-HCl pH 8.4*	120 µl	1 M	40 mM
MgCl <sub>2</sub>	39.6 µl	1 M	13.2 mM
KCl	112.5 µl	2 M	75 mM
DTT	30 µl	1 M	10 mM
DMSO	450 µl	100%	11%
water	247.9 µl		
<b>total volume</b>	1000 µl		

#### Buffer with DMSO

\*Tris-HCl pH 8.4 is made in-house by titrating Tris-HCl pH 8.0 with NaOH pellet and pH determined by pH meter.

	vol.	stock conc.	conc. in RM
Tris-HCl pH 8.4	120 µl	1 M	40 mM
MgCl <sub>2</sub>	39.6 µl	1 M	13.2 mM
KCl	112.5 µl	2 M	75 mM
DTT	30 µl	1 M	10 mM
water	697.9 µl		
<b>total volume</b>	1000 µl		

#### Buffer without DMSO

	vol.	stock conc.	conc. in RM
dNTP	0.22 µl each	100 mM	1 mM each
NTP	0.88 µl each	100 mM	4 mM each
<b>total volume</b>	4.4 µl		

**Nucleotide mix (incl. 10% excess)**

	vol.	stock conc.	conc. in RM
diluted RNase H	0.17 µl	500 U/ml	3.75 U/ml
Photocript RT	0.28 µl	200000 U/ml	2500 U/ml
T7 polymerase	2.75 µl	50000 U/ml	6250 U/ml
BSA	0.13 µl	20 mg/ml	0.12 mg/ml
buffer without DMSO	1.78 µl		
water	0.40 µl		
<b>total volume</b>	5.5 µl		

**Enzyme mix (incl. 10% excess)**

	vol.	stock conc.
RNase H	5 µl	5000 U/ml
BSA (0.48mg/ml)	1.2 µl	20 mg/ml
buffer without DMSO	16.67 µl	
water	27.13 µl	
<b>total volume</b>	50 µl	

**Diluted RNase H**

### (Option B) NASBA reaction with lateral flow dipstick detection

For detection with a lateral flow assay, a NASBA lyophilised kit is used with the constitution of the reaction mixture shown below.

Take 4 µl from the product of Step 1 (saliva lysate) and add into the NASBA reaction mixture (without the enzyme mix) to make a total volume of 60 µl. Incubate at 95 °C for 5 min followed by a 10-min incubation at 41 °C.

Following that, 20 µl enzyme mix is added into the reaction and incubated at 41 °C for a further of 90-120 min. Take the reaction product to the sample well of a PCRD test cassette. Results will be shown within 10 min.

## 3 Library construction for NGS

To allow for pooled sequencing of NASBA reaction end products, barcode sequences are added upstream of each of the forward and reverse primers (Figure 3a). In addition, an Illumina sequencing adaptor is added upstream of the forward primer barcode sequence as a universal PCR handle (see Materials and reagents section for the exact sequence).

Here, 2 µl NASBA end products from each sample are first pooled into a single tube. Pooled products are then column purified to remove residual NASBA primers (QIAquick PCR Purification Kit). PCR is performed on the column purified pooled sample using two NGS indexing primers. Here, we have designed a customised NGS primer containing the T7

polymerase promoter sequence (see Materials and reagents section for the exact sequence) at the P5 end and used a standard TruSeq sequencing primer at the P7 side. A PCR mix is made based on the table below. A standard PCR program is used with longer elongation time and minimal cycle number to reduce barcode hopping.

	vol.
2x PCR mix (KAPA HIFI HotStart ReadyMix)	20 µl
P5 end primer (10 µM)	1 µl
P7 end primer (10 µM)	1 µl
Column purified NASBA product (~3.5 ng dsDNA)	4 µl
Nuclease free water	14 µl

Library construction PCR

temperature	time	cycle number
95 °C	3 min	1
98 °C	20 s	15
60 °C	15 s	
72 °C	30 s	
72 °C	4 min	
		1

After the PCR, an AMPure bead-based double size selection is carried out (0.55x and 0.75x) to enrich for products of interest. In this study, a MiSeq Reagent Kit v2 (300- cycles) was used for NGS.

## 4 Analysis of NGS results

To analyse the INSIGHT NGS data, sequences in FASTQ files are first trimmed to leave the first 80 nucleotides for both read 1 and read 2 using FASTX\_trimmer. The trimmed read 1 and paired read 2 are then merged by FLASH. The merged sequence is compared with the reference viral genome sequence (NNNNNACACCTGTGCCTGTTAAACCATTGAAGTTGAAATTGACACATTTGTT TTTAACCAAATTAGTAGACTTTTTAGGTCCACAAACAGTTGCTGGNNNNN, N stands for the barcode position), and only those with a hamming distance less than or equal to 2 are extracted. Here, only substitutions were allowed while insertion- and deletion- containing reads were filtered out. The first 5 nt and the final 5 nt regions of all extracted sequences correspond respectively to the right barcode and the reverse complement of the left barcode. Diagnostic results for sequenced NASBA samples are determined according to the read counts of their corresponding sample-specific barcode pairs. More details can be found in [www.github.com/suochenqu/INSIGHT](http://www.github.com/suochenqu/INSIGHT).